Rockville, MD, United States
Rockville, MD, United States

Time filter

Source Type

News Article | April 27, 2017
Site: www.eurekalert.org

A new study found no evidence that a commercially available e-cigarette vapor promotes the development of cancer in laboratory cells. In contrast, smoke from a reference cigarette was positive for cancer-promoting activity at very low concentrations. The findings suggest that e-cigarettes may provide a safer alternative to traditional cigarettes. "This is the first time this particular test, the Bhas 42 assay, has been used to compare tobacco and nicotine products," said Dr. Damien Breheny, lead author of the Environmental and Molecular Mutagenesis study. "It is one of a series of tests being developed and refined by British American Tobacco to compare the relative biological effects of e-cigarettes and tobacco-heating products with conventional cigarettes." The authors are employees of British American Tobacco or BioReliance. BioReliance conducted all experimental work and was funded by British American Tobacco.


PubMed | University of Missouri, Bioreliance and Cell science and Development
Type: | Journal: Biotechnology and bioengineering | Year: 2016

Contamination by the parvovirus minute virus of mice (MVM) remains a challenge in Chinese hamster ovary (CHO) biopharmaceutical production processes. Although infrequent, infection of a bioreactor can be catastrophic for a manufacturer, can impact patient drug supply and safety, and can have regulatory implications. We evaluated engineering a CHO parental cell line (CHOZN


Bohnenberger S.,Harlan Cytotest Cell Research Harlan CCR GmbH | Bruce S.W.,BioReliance | Kunkelmann T.,Harlan Cytotest Cell Research Harlan CCR GmbH | Pant K.,BioReliance | And 4 more authors.
Mutation Research - Genetic Toxicology and Environmental Mutagenesis | Year: 2012

This catalogue is a display of Syrian hamster embryo (SHE) cell colony photos representative of the cell transformation assay (CTA) carried out at pH 6.7. It is intended as a visual aid for the identification and the scoring of cell colonies in the conduct of the assay.A proper training from experienced personnel together with the protocol reported in this issue and the present photo catalogue will support method transfer and consistency in the assay results. © 2011 Elsevier B.V.


Pant K.,BioReliance | Bruce S.W.,BioReliance | Sly J.E.,BioReliance | Kunkelmann T.,Harlan Cytotest Cell Research GmbH Harlan CCR | And 5 more authors.
Mutation Research - Genetic Toxicology and Environmental Mutagenesis | Year: 2012

The Syrian hamster embryo (SHE) cell transformation assay (CTA) is an important in vitro method that is highly predictive of rodent carcinogenicity. It is a key method for reducing animal usage for carcinogenicity prediction. The SHE assay has been used for many years primarily to investigate and identify potential rodent carcinogens thereby reducing the number of 2-year bioassays performed in rodents. As for other assays with a long history of use, the SHE CTA has not undergone formal validation. To address this, the European Centre for the Validation of Alternative Methods (ECVAM) coordinated a prevalidation study. The aim of this study was to evaluate the within-laboratory reproducibility, test method transferability, and between-laboratory reproducibility and to develop a standardised state-of-the-art protocol for the SHE CTA at pH 6.7. Formal ECVAM principles for criteria on reproducibility (including the within-laboratory reproducibility, the transferability and the between-laboratories reproducibility) were applied. In addition to the assessment of reproducibility, this study helped define a standard protocol for use in developing an Organisation for Economic Co-operation and Development (OECD) test guideline for the SHE CTA. Six compounds were evaluated in this study: benzo(a)pyrene, 3-methylcholanthrene, o-toluidine HCl, 2,4-diaminotoluene, phthalic anhydride and anthracene. Results of this study demonstrate that a protocol is available that is transferable between laboratories, and that the SHE CTA at pH 6.7 is reproducible within- and between-laboratories. © 2011 Elsevier B.V.


News Article | November 3, 2016
Site: marketersmedia.com

— Growing research in cell line development and advancements in cell preservation techniques are the key factors fostering the market growth. In addition, increasing awareness of stem cell therapies, growth in cell bank facilities around the world are some of the key factors influencing the market growth. On the other hand, differing legal and ethical issues among countries throughout collection of cells, and therapies costs are inhibiting the market growth. The stem cell banking leads the market globally with the biggest market share and is expected to grow with a high CAGR during the forecast period. The growth of this segment is attributed to growing number of cord blood banks, and services among countries. North America is anticipated to hold the largest share in global market due to increasing demand from U.S. Asia Pacific is expected to witness huge growth due to encouraging government schemes and growing adoption of cell therapies. Some of the key players in global cell banking outsourcing market include CordLife, Cleancells, Charles River Laboratories, BSL Bioservice, BioReliance, BioOutsource/Sartorius, Covance, LifeCell International Pvt. Ltd., Goodwin Biotechnology Inc., GlobalStem Inc., Cryo-Cell International Inc., Cryobanks International India, Lonza, PX’Therapeutics SA, Wuxi Apptec, Tran-Scell Biologics Pvt. Ltd., Toxikon Corporation, Texcell, SGS Life Sciences, and Reliance Life Sciences. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements About Stratistics MRC We offer wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services and Full Time Equivalent (FTE) services in the research world. We explore the market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends. Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects. For more information, please visit http://www.strategymrc.com/


Bryce S.M.,Litron Laboratories, Ltd. | Shi J.,BioReliance | Nicolette J.,Abbott Laboratories | Diehl M.,Abbott Laboratories | And 5 more authors.
Environmental and Molecular Mutagenesis | Year: 2010

A flow cytometric method for analyzing suspension cell cultures for micronucleus content has been previously reported (Avlasevich et al. [2006]: Environ Mol Mutagen 47: 56-66). The experiments described herein were undertaken to evaluate the compatibility of this method (In Vitro MicroFlow®) with attachment cells. Initially, CHO-K1 cells were studied in nine independent experiments using mitomycin C and cyclophosphamide. The results demonstrated the effectiveness of the cell processing procedure, and also provided historical control data that were useful for setting criteria for making positive calls. Subsequently, CHO-K1 cells were treated with methyl methanesulfonate, mitomycin C, etoposide, vinblastine sulfate, dexamethasone, and sodium chloride. Whereas the four genotoxicants were each observed to increase micronucleus frequencies, the nongenotoxicants induced no such response up to cytotoxic concentrations. Following this initial work, inter-laboratory transferability was evaluated across three sites using a common cell staining and analysis protocol for CHO-K1 or V79 cells that had been treated with the ten chemicals listed in Annex 3 of the OECD Draft Proposal for a New Guideline 487: In Vitro Mammalian Cell Micronucleus Test. With the exception of benzo[a]pyrene at one site, each laboratory observed increased micronucleus frequencies for the genotoxicants, whereas no significant induction occurred with the non-genotoxicants. Interestingly, the method appeared to distinguish between genotoxic modes of action, as only aneugens increased the average micronucleus fluorescence intensity and the frequency of hypodiploid nuclei. Collectively, these data suggest that flow cytometry is capable of providing reliable micronucleus counts, and that additional information is obtained that appears to discern genotoxic modes of action. © 2009 Wiley-Liss, Inc.


News Article | November 22, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global Cell Banking Outsourcing market is expected to grow from $3.42 billion in 2015 to reach $10.67 billion by 2022 with a CAGR of 17.6%. Growing research in cell line development and advancements in cell preservation techniques are the key factors fostering the market growth. In addition, increasing awareness of stem cell therapies, growth in cell bank facilities around the world are some of the key factors influencing the market growth. On the other hand, differing legal and ethical issues among countries throughout collection of cells, and therapies costs are inhibiting the market growth. Access the complete report at: http://www.strategymrc.com/report/cell-banking-outsourcing-market The stem cell banking leads the market globally with the biggest market share and is expected to grow with a high CAGR during the forecast period. The growth of this segment is attributed to growing number of cord blood banks, and services among countries. North America is anticipated to hold the largest share in global market due to increasing demand from U.S. Asia Pacific is expected to witness huge growth due to encouraging government schemes and growing adoption of cell therapies. Some of the key players in global cell banking outsourcing market include CordLife, Cleancells, Charles River Laboratories, BSL Bioservice, BioReliance, BioOutsource/Sartorius, Covance, LifeCell International Pvt. Ltd., Goodwin Biotechnology Inc., GlobalStem Inc., Cryo-Cell International Inc., Cryobanks International India, Lonza, PX’Therapeutics SA, Wuxi Apptec, Tran-Scell Biologics Pvt. Ltd., Toxikon Corporation, Texcell, SGS Life Sciences, and Reliance Life Sciences. Request for a sample at: http://www.strategymrc.com/report/cell-banking-outsourcing-market Phases Covered: • Characterization • Preparation • Storage • Testing o Viral Cell Bank Safety Testing o Microbial Cell Bank Safety Testing o Gene Expression Testing o Karyology Testing o Gene Sequencing Testing Bank Types Covered: • Master Cell Banking • Viral Cell Banking • Working Cell Banking Cell Types Covered: • Stem Cell Banking o IPS Stem Cell Banking o Embryonic Cell Banking o Dental Stem Cell Banking o Adult Stem Cell Banking o Cord Cell Banking • Non-Stem Cell Banking Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain      o Rest of Europe  • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements


News Article | November 18, 2016
Site: www.newsmaker.com.au

Global Cell Banking Outsourcing market is expected to grow from $3.42 billion in 2015 to reach $10.67 billion by 2022 with a CAGR of 17.6%. Growing research in cell line development and advancements in cell preservation techniques are the key factors fostering the market growth. In addition, increasing awareness of stem cell therapies, growth in cell bank facilities around the world are some of the key factors influencing the market growth. On the other hand, differing legal and ethical issues among countries throughout collection of cells, and therapies costs are inhibiting the market growth. The stem cell banking leads the market globally with the biggest market share and is expected to grow with a high CAGR during the forecast period. The growth of this segment is attributed to growing number of cord blood banks, and services among countries. North America is anticipated to hold the largest share in global market due to increasing demand from U.S. Asia Pacific is expected to witness huge growth due to encouraging government schemes and growing adoption of cell therapies. Some of the key players in global cell banking outsourcing market include CordLife, Cleancells, Charles River Laboratories, BSL Bioservice, BioReliance, BioOutsource/Sartorius, Covance, LifeCell International Pvt. Ltd., Goodwin Biotechnology Inc., GlobalStem Inc., Cryo-Cell International Inc., Cryobanks International India, Lonza, PX’Therapeutics SA, Wuxi Apptec, Tran-Scell Biologics Pvt. Ltd., Toxikon Corporation, Texcell, SGS Life Sciences, and Reliance Life Sciences. Regions Covered:  • North America  o US  o Canada  o Mexico  • Europe  o Germany  o France  o Italy  o UK  o Spain  o Rest of Europe  • Asia Pacific  o Japan  o China  o India  o Australia  o New Zealand  o Rest of Asia Pacific  • Rest of the World  o Middle East  o Brazil  o Argentina  o South Africa  o Egypt What our report offers:  - Market share assessments for the regional and country level segments  - Market share analysis of the top industry players  - Strategic recommendations for the new entrants  - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets  - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)  - Strategic recommendations in key business segments based on the market estimations  - Competitive landscaping mapping the key common trends  - Company profiling with detailed strategies, financials, and recent developments  - Supply chain trends mapping the latest technological advancements About Us Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.


News Article | September 9, 2016
Site: www.biosciencetechnology.com

MilliporeSigma  launched a first-of-its-kind gene editing technology to modify CHO cell lines to be resistant to minute virus of mice (MVM), a common contamination threat that remains despite the shift to chemically-defined, animal component-free manufacturing processes. CHO cells are commonly used in the manufacture of biologics. The new Centinel technology targets genes which play a role in MVM susceptibility. Viral contaminations like MVM can have major consequences for biopharmaceutical manufacturers, costing hundreds of millions of dollars, according to industry reports. The greatest impact of such contamination is on patients, as access to therapies can be put in jeopardy. The technology provides manufacturers with an additional path for mitigating the risk of MVM contamination, while maintaining an equivalent level of protein quality and cell line productivity. Under the program, the company can modify customers’ CHO cell lines to provide viral resistance to MVM. A patent application has been submitted for the technology used in the gene editing approach to viral resistance. The company’s BioReliance testing services can validate MVM resistance and demonstrate the virus is not propagated in the cell line. Alternatively, customers can purchased the zinc finger nuclease pairs to engineer cell lines directly. The technology builds on the company’s expertise in gene editing and biomanufacturing processes, as well as its in-depth understanding of the regulatory environment. In addition to enhancing the safety of biomanufacturing, MilliporeSigma is also applying this expertise and approach to develop other technologies and services, including those supporting the cell therapy industry.


Onions D.,BioReliance | Kolman J.,BioReliance
Biologicals | Year: 2010

There has been an upsurge of interest in developing new veterinary and human vaccines and, in turn, this has involved the development of new mammalian and insect cell substrates. Excluding adventitious agents from these cells can be problematic, particularly for cells derived from species with limited virological investigation. Massively parallel sequencing is a powerful new method for the identification of viruses and other adventitious agents, without prior knowledge of the nature of the agent. We have developed methods using random priming to detect viruses in the supernatants from cell substrates or in virus seed stocks. Using these methods we have recently discovered a new parvovirus in bovine serum. When applied to sequencing the transcriptome, massively parallel sequencing can reveal latent or silent infections. Enormous amounts of data are developed in this process usually between 100 and 400. Mbp. Consequently, sophisticated bioinformatic algorithms are required to analyse and verify virus targets. © 2010.

Loading BioReliance collaborators
Loading BioReliance collaborators